BlackRock’s Pernix Therapeutics Holdings, Inc. PTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q1 | – | Sell |
-228,243
| Closed | -$96K | – | 5161 |
|
|
2018
Q4 | $96K | Buy |
228,243
+3,419
| +2% | +$2.13K | ﹤0.01% | 4360 |
|
|
2018
Q3 | $217K | Buy |
224,824
+2,494
| +1% | +$4.17K | ﹤0.01% | 4303 |
|
|
2018
Q2 | $540K | Buy |
222,330
+12,882
| +6% | +$31.5K | ﹤0.01% | 4083 |
|
|
2018
Q1 | $500K | Buy |
209,448
+68
| +0% | +$172 | ﹤0.01% | 4047 |
|
|
2017
Q4 | $502K | Buy |
209,380
+2,572
| +1% | +$7.12K | ﹤0.01% | 4053 |
|
|
2017
Q3 | $651K | Buy |
206,808
+1,528
| +0.7% | +$4.9K | ﹤0.01% | 4010 |
|
|
2017
Q2 | $825K | Buy |
205,280
+22,480
| +12% | +$97.9K | ﹤0.01% | 3893 |
|
|
2017
Q1 | $677K | Buy |
+182,800
| New | +$574K | ﹤0.01% | 3896 |
|
|
2016
Q2 | – | Sell |
-154
| Closed | -$2K | – | 3897 |
|
|
2016
Q1 | $2K | Buy |
154
+70
| +83% | +$1.39K | ﹤0.01% | 3495 |
|
|
2015
Q4 | $2K | Hold |
84
| – | – | ﹤0.01% | 3356 |
|
|
2015
Q3 | $3K | Hold |
84
| – | – | ﹤0.01% | 3150 |
|
|
2015
Q2 | $5K | Hold |
84
| – | – | ﹤0.01% | 3148 |
|
|
2015
Q1 | $9K | Hold |
84
| – | – | ﹤0.01% | 2819 |
|
|
2014
Q4 | $8K | Hold |
84
| – | – | ﹤0.01% | 2923 |
|
|
2014
Q3 | $6K | Hold |
84
| – | – | ﹤0.01% | 3044 |
|
|
2014
Q2 | $8K | Buy |
+84
| New | +$5.15K | ﹤0.01% | 2964 |
|
BlackRock's PTX Position: Q1 2019 in Review
BlackRock sold out of Pernix Therapeutics Holdings, Inc. (PTX) in Q1 2019, closing a stake of 228,243 shares — an estimated $96K sold.
BlackRock first reported a position in PTX in Q2 2014 and held it in 16 quarters. The position peaked at $825K in Q2 2017. 1 fund tracked by Wall St. Rank holds PTX as of Q1 2019.
- BlackRock reported no remaining Pernix Therapeutics Holdings, Inc. position as of Q1 2019 after selling out during the quarter.
- BlackRock sold 228,243 Pernix Therapeutics Holdings, Inc. shares in Q1 2019, an estimated $96K.
- BlackRock first reported a position in Pernix Therapeutics Holdings, Inc. in Q2 2014 and held it in 16 quarters.
- BlackRock's Pernix Therapeutics Holdings, Inc. position peaked at $825K in Q2 2017.
- 1 fund tracked by Wall St. Rank held Pernix Therapeutics Holdings, Inc. as of Q1 2019.
Based on BlackRock's 13F filing for Q1 2019, filed 9 May 2019.